Nuvation Bio Statistics
Total Valuation
Nuvation Bio has a market cap or net worth of $723.49 million. The enterprise value is $229.72 million.
Important Dates
The next confirmed earnings date is Wednesday, May 7, 2025, after market close.
Earnings Date | May 7, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Nuvation Bio has 339.67 million shares outstanding. The number of shares has increased by 22.79% in one year.
Current Share Class | 338.67M |
Shares Outstanding | 339.67M |
Shares Change (YoY) | +22.79% |
Shares Change (QoQ) | +23.16% |
Owned by Insiders (%) | 24.92% |
Owned by Institutions (%) | 51.08% |
Float | 229.07M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 72.72 |
Forward PS | 103.28 |
PB Ratio | 1.55 |
P/TBV Ratio | 1.58 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 29.18 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.04, with a Debt / Equity ratio of 0.02.
Current Ratio | 9.04 |
Quick Ratio | 8.91 |
Debt / Equity | 0.02 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -491.37 |
Financial Efficiency
Return on equity (ROE) is -106.27% and return on invested capital (ROIC) is -19.36%.
Return on Equity (ROE) | -106.27% |
Return on Assets (ROA) | -18.02% |
Return on Invested Capital (ROIC) | -19.36% |
Return on Capital Employed (ROCE) | -34.74% |
Revenue Per Employee | $35,786 |
Profits Per Employee | -$2.58M |
Employee Count | 220 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.11% in the last 52 weeks. The beta is 1.47, so Nuvation Bio's price volatility has been higher than the market average.
Beta (5Y) | 1.47 |
52-Week Price Change | -20.11% |
50-Day Moving Average | 1.98 |
200-Day Moving Average | 2.56 |
Relative Strength Index (RSI) | 59.67 |
Average Volume (20 Days) | 3,350,984 |
Short Selling Information
The latest short interest is 30.81 million, so 9.07% of the outstanding shares have been sold short.
Short Interest | 30.81M |
Short Previous Month | 28.39M |
Short % of Shares Out | 9.07% |
Short % of Float | 13.45% |
Short Ratio (days to cover) | 10.26 |
Income Statement
In the last 12 months, Nuvation Bio had revenue of $7.87 million and -$567.94 million in losses. Loss per share was -$2.11.
Revenue | 7.87M |
Gross Profit | 795,000 |
Operating Income | -167.56M |
Pretax Income | -510.72M |
Net Income | -567.94M |
EBITDA | -166.87M |
EBIT | -167.56M |
Loss Per Share | -$2.11 |
Full Income Statement Balance Sheet
The company has $502.69 million in cash and $8.92 million in debt, giving a net cash position of $493.78 million or $1.45 per share.
Cash & Cash Equivalents | 502.69M |
Total Debt | 8.92M |
Net Cash | 493.78M |
Net Cash Per Share | $1.45 |
Equity (Book Value) | 463.79M |
Book Value Per Share | 1.37 |
Working Capital | 468.01M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$130.41 million and capital expenditures -$162,000, giving a free cash flow of -$130.58 million.
Operating Cash Flow | -130.41M |
Capital Expenditures | -162,000 |
Free Cash Flow | -130.58M |
FCF Per Share | -$0.38 |
Full Cash Flow Statement Margins
Gross Margin | 10.10% |
Operating Margin | -2,128.25% |
Pretax Margin | -7,213.76% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Nuvation Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -22.79% |
Shareholder Yield | n/a |
Earnings Yield | -78.50% |
FCF Yield | -18.05% |
Analyst Forecast
The average price target for Nuvation Bio is $8.20, which is 285.88% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $8.20 |
Price Target Difference | 285.88% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | 118.73% |
EPS Growth Forecast (5Y) | -24.15% |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Nuvation Bio has an Altman Z-Score of 3.31 and a Piotroski F-Score of 1.
Altman Z-Score | 3.31 |
Piotroski F-Score | 1 |